Progyny Director Kevin Gordon Sells Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: NASDAQ.COM
- Share Sale Details: Kevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of approximately $24.99 per share, totaling around $137,000, which represented 20.13% of his direct holdings, indicating a cautious approach towards the company's future.
- Ownership Structure: Post-sale, Gordon retains 15,027 shares indirectly through the Kevin Gordon Revocable Declaration of Trust, reflecting his continued confidence in Progyny despite the partial liquidation of his stake.
- Company Performance: Progyny reported a 1.4% year-over-year sales growth in Q1 2026, reaching $328 million, although revenue growth stalled due to the loss of a major client, yet gross profit increased by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Outlook: Progyny expects total revenue to rise by 5.9% to 9.0% in 2026 and has approved a $200 million share repurchase program, indicating strong confidence in future market opportunities and a commitment to shareholder value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGNY
Wall Street analysts forecast PGNY stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 25.690
Low
26.00
Averages
29.75
High
34.00
Current: 25.690
Low
26.00
Averages
29.75
High
34.00
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Progyny Director Kevin Gordon Sells Shares
- Share Sale Details: Kevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of approximately $24.99 per share, totaling around $137,000, which represented 20.13% of his direct holdings, indicating a cautious approach towards the company's future.
- Ownership Structure: Post-sale, Gordon retains 15,027 shares indirectly through the Kevin Gordon Revocable Declaration of Trust, reflecting his continued confidence in Progyny despite the partial liquidation of his stake.
- Company Performance: Progyny reported a 1.4% year-over-year sales growth in Q1 2026, reaching $328 million, although revenue growth stalled due to the loss of a major client, yet gross profit increased by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Outlook: Progyny expects total revenue to rise by 5.9% to 9.0% in 2026 and has approved a $200 million share repurchase program, indicating strong confidence in future market opportunities and a commitment to shareholder value.
See More
Progyny Insider Sells Shares Amid Positive Market Outlook
- Insider Share Sale: Progyny's Director Kevin K. Gordon sold 5,500 shares on May 27, 2026, for approximately $137,000, reducing his direct holdings to 6,792 shares, which indicates confidence in the company's future despite the sale.
- Ownership Proportion Analysis: This transaction represented 20.13% of Gordon's direct holdings, reflecting a significant decrease in his ownership over the past year, while he retains 15,027 indirect shares, demonstrating trust in the company's long-term prospects.
- Company Financial Performance: Progyny reported $328 million in revenue for Q1 2026, a 1.4% year-over-year increase, and despite a slowdown due to losing a major client, gross profit rose by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Expectations: Progyny anticipates total revenue growth of 5.9% to 9.0% in 2026, and the board has approved a $200 million share repurchase program, indicating strong confidence in future performance and commitment to shareholders.
See More
Progyny Survey Reveals Importance of Human-Centric Healthcare
- Stress Management Challenges: The survey revealed that 71% of respondents felt their healthcare journey added stress to their daily lives, with primary sources being financial impacts, system complexity, and work-life balance issues, indicating a pressing need for improved healthcare services.
- Demand for Human Support: Over 70% of respondents expressed a desire for knowledgeable human support in every healthcare experience, highlighting the importance of interpersonal connections in an increasingly digital healthcare landscape, which may drive further development of Progyny's service model.
- Significant PCA Support Effects: 60% of respondents reported that interactions with Progyny Care Advocates (PCAs) helped reduce stress related to their care, with more than 75% stating that PCA support significantly alleviated their anxiety, demonstrating a strong market demand for personalized services.
- Importance of Emotional Support: The survey also found that 63% of respondents felt more educated and empowered in their healthcare journey, while 54% believed that PCAs helped them communicate better with providers, underscoring the critical role of emotional support in the healthcare process.
See More
Progyny Approves $200M Share Repurchase Program
- Share Repurchase Program: Progyny's board has approved a share repurchase program of up to $200 million, which will be funded through available cash balances, aimed at enhancing shareholder value and boosting market confidence.
- Stock Price Reaction: Following the announcement, Progyny's stock rose 1.6% in premarket trading to $25.28, indicating a positive market response to the company's repurchase initiative.
- Future Financial Outlook: Progyny anticipates revenue for 2026 to be between $1.365 billion and $1.405 billion, while adjusted EBITDA is expected to rise to between $232 million and $244 million, showcasing the company's growth potential.
- Strategic Market Implications: By implementing the share repurchase, Progyny not only strengthens its capital structure but may also attract more investor interest, thereby further solidifying its position in the competitive healthcare market.
See More
Progyny Authorized to Repurchase $200 Million in Stock
- Buyback Program Initiated: Progyny has announced authorization to repurchase up to $200 million of its common stock, which will be funded by cash, aimed at enhancing shareholder value and boosting market confidence.
- Positive Market Reaction: Following the buyback announcement, Progyny shares rose 1.04% in pre-market trading on Nasdaq, reaching $25.14 per share, indicating investor optimism regarding the company's future prospects.
- Clear Funding Source: The buyback program will be fully supported by the company's cash reserves, demonstrating Progyny's strong financial position and its ability to effectively utilize capital to reward shareholders.
- Strategic Implications: By implementing the stock repurchase, Progyny not only aims to enhance earnings per share but also seeks to strengthen its market position in the competitive women's health sector, attracting more investor interest.
See More
Latest Wall Street Ratings and Price Target Adjustments
- Micron Price Target Increase: Citigroup raised Micron Technology's price target from $425 to $840, anticipating a 40% increase in DRAM prices in Q2, which will significantly enhance its market competitiveness.
- Jazz Pharmaceuticals Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy and raised its price target from $188 to $307, driven by increased confidence in the commercial potential of its cancer drug Ziihera, which is expected to boost company performance.
- Nvidia Price Target Boost: HSBC raised Nvidia's price target from $295 to $325, expecting the company to exceed market expectations in its upcoming earnings report, further enhancing its profitability.
- Costco Price Target Increase: Oppenheimer raised Costco's price target from $1,100 to $1,160, believing that its defensive characteristics and superior value proposition will continue to drive market share growth, with potential catalysts for a special dividend or stock split.
See More
Progyny Director Kevin Gordon Sells Shares
- Share Sale Details: Kevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of approximately $24.99 per share, totaling around $137,000, which represented 20.13% of his direct holdings, indicating a cautious approach towards the company's future.
- Ownership Structure: Post-sale, Gordon retains 15,027 shares indirectly through the Kevin Gordon Revocable Declaration of Trust, reflecting his continued confidence in Progyny despite the partial liquidation of his stake.
- Company Performance: Progyny reported a 1.4% year-over-year sales growth in Q1 2026, reaching $328 million, although revenue growth stalled due to the loss of a major client, yet gross profit increased by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Outlook: Progyny expects total revenue to rise by 5.9% to 9.0% in 2026 and has approved a $200 million share repurchase program, indicating strong confidence in future market opportunities and a commitment to shareholder value.
See More
Progyny Insider Sells Shares Amid Positive Market Outlook
- Insider Share Sale: Progyny's Director Kevin K. Gordon sold 5,500 shares on May 27, 2026, for approximately $137,000, reducing his direct holdings to 6,792 shares, which indicates confidence in the company's future despite the sale.
- Ownership Proportion Analysis: This transaction represented 20.13% of Gordon's direct holdings, reflecting a significant decrease in his ownership over the past year, while he retains 15,027 indirect shares, demonstrating trust in the company's long-term prospects.
- Company Financial Performance: Progyny reported $328 million in revenue for Q1 2026, a 1.4% year-over-year increase, and despite a slowdown due to losing a major client, gross profit rose by 10% to $83.1 million, showcasing efforts to enhance operational efficiency.
- Future Growth Expectations: Progyny anticipates total revenue growth of 5.9% to 9.0% in 2026, and the board has approved a $200 million share repurchase program, indicating strong confidence in future performance and commitment to shareholders.
See More
Progyny Survey Reveals Importance of Human-Centric Healthcare
- Stress Management Challenges: The survey revealed that 71% of respondents felt their healthcare journey added stress to their daily lives, with primary sources being financial impacts, system complexity, and work-life balance issues, indicating a pressing need for improved healthcare services.
- Demand for Human Support: Over 70% of respondents expressed a desire for knowledgeable human support in every healthcare experience, highlighting the importance of interpersonal connections in an increasingly digital healthcare landscape, which may drive further development of Progyny's service model.
- Significant PCA Support Effects: 60% of respondents reported that interactions with Progyny Care Advocates (PCAs) helped reduce stress related to their care, with more than 75% stating that PCA support significantly alleviated their anxiety, demonstrating a strong market demand for personalized services.
- Importance of Emotional Support: The survey also found that 63% of respondents felt more educated and empowered in their healthcare journey, while 54% believed that PCAs helped them communicate better with providers, underscoring the critical role of emotional support in the healthcare process.
See More
Progyny Approves $200M Share Repurchase Program
- Share Repurchase Program: Progyny's board has approved a share repurchase program of up to $200 million, which will be funded through available cash balances, aimed at enhancing shareholder value and boosting market confidence.
- Stock Price Reaction: Following the announcement, Progyny's stock rose 1.6% in premarket trading to $25.28, indicating a positive market response to the company's repurchase initiative.
- Future Financial Outlook: Progyny anticipates revenue for 2026 to be between $1.365 billion and $1.405 billion, while adjusted EBITDA is expected to rise to between $232 million and $244 million, showcasing the company's growth potential.
- Strategic Market Implications: By implementing the share repurchase, Progyny not only strengthens its capital structure but may also attract more investor interest, thereby further solidifying its position in the competitive healthcare market.
See More
Progyny Authorized to Repurchase $200 Million in Stock
- Buyback Program Initiated: Progyny has announced authorization to repurchase up to $200 million of its common stock, which will be funded by cash, aimed at enhancing shareholder value and boosting market confidence.
- Positive Market Reaction: Following the buyback announcement, Progyny shares rose 1.04% in pre-market trading on Nasdaq, reaching $25.14 per share, indicating investor optimism regarding the company's future prospects.
- Clear Funding Source: The buyback program will be fully supported by the company's cash reserves, demonstrating Progyny's strong financial position and its ability to effectively utilize capital to reward shareholders.
- Strategic Implications: By implementing the stock repurchase, Progyny not only aims to enhance earnings per share but also seeks to strengthen its market position in the competitive women's health sector, attracting more investor interest.
See More
Latest Wall Street Ratings and Price Target Adjustments
- Micron Price Target Increase: Citigroup raised Micron Technology's price target from $425 to $840, anticipating a 40% increase in DRAM prices in Q2, which will significantly enhance its market competitiveness.
- Jazz Pharmaceuticals Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy and raised its price target from $188 to $307, driven by increased confidence in the commercial potential of its cancer drug Ziihera, which is expected to boost company performance.
- Nvidia Price Target Boost: HSBC raised Nvidia's price target from $295 to $325, expecting the company to exceed market expectations in its upcoming earnings report, further enhancing its profitability.
- Costco Price Target Increase: Oppenheimer raised Costco's price target from $1,100 to $1,160, believing that its defensive characteristics and superior value proposition will continue to drive market share growth, with potential catalysts for a special dividend or stock split.
See More
